Dry eye showdown: SYSTANE PRO takes on MIEBO in new trial

NCT ID NCT07243275

First seen Jun 25, 2026 · Last updated Aug 07, 2026 · Updated 3 times

Summary

This study compares two eye drops—SYSTANE PRO and MIEBO—to see if SYSTANE PRO works as well as MIEBO for treating dry eye disease. About 260 adults with moderate dry eye will use one of the two drops for one month. The main goal is to measure changes in dry eye symptoms using a standard questionnaire.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
SYSTANE PRO (hyaluronate, nano-sized lipids, HP-Guar) and MIEBO (perfluorohexyloctane)
What this could lead to
If SYSTANE PRO works as well as MIEBO, it could offer a more affordable or accessible option for managing dry eye symptoms.
What could go wrong
This is a Phase 4 trial comparing two existing treatments, so no major breakthrough is expected. The study is relatively small and may not show a clear difference between the two drops.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRY EYE DISEASE (DED) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Eye Research Foundation

    Newport Beach, California, 92663, United States

  • Indiana Universtiy School of Optometry

    Bloomington, Indiana, 47408, United States

  • Kannarr Eye Care

    Pittsburg, Kansas, 66762, United States

  • Southern College of Optometry

    Memphis, Tennessee, 38104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.